Blood–brain barrier penetrating liposomes with synergistic chemotherapy for glioblastoma treatment

Zhang, Ying; Qu, Haijing; Xue, Xiangdong

doi:10.1039/d1bm01506k

Cited by 25 publications

(20 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most recent study on TMZ-liposomes targeting the BBB was published by Zhang et al [83]. The authors developed a glucose-functionalized liposome (gLTP) made of TMZ and pro-apoptotic peptide (PAP) to achieve synergistic efficacy toward GBM.…”

Section: Targeting Liposomesmentioning

confidence: 99%

“…In the attempt of maximizing BBB penetration by liposomes carrying TMZ, Zhang et al prepared glucose-decorated liposomes containing TMZ and PAP (TMZ: PAP, 6:4, w/w) through THF [83]. They mixed soy PC, cholesterol, and DSPE-PEG2000-MA (maltobionic acid) in a round-bottom flask containing a methanol/chloroform mixture.…”

Section: Thin-film Hydration (Thf)mentioning

confidence: 99%

“…The liposomes decorated with glucose prepared by Zhang et al were characterized in view of their size, zeta potential, and morphology by DLS and TEM [83]. The obtained values of hydrodynamic diameter and zeta potential for the sphere-like liposomes were 133 nm (with PDI of 0.246) and −5.68 mV, respectively.…”

Section: Physico-chemical Propertiesmentioning

confidence: 99%

“…Transporter-mediated transcytosis, when glucose is used as the transporter [83];  Adsorptive transcytosis, when the transport is based on the electrostatic interactions between the negatively charged membrane and the positively charged liposomes (cationic liposomes) [47];  Receptor-mediated transcytosis, strategy fulfilled out by decorating the targeting TMZ-liposome with Tf, An2 [78,80].…”

mentioning

confidence: 99%

See 3 more Smart Citations

Liposomal-Based Formulations: A Path from Basic Research to Temozolomide Delivery Inside Glioblastoma Tissue

et al. 2022

View full text Add to dashboard Cite

Glioblastoma (GBM) is a lethal brain cancer with a very difficult therapeutic approach and ultimately frustrating results. Currently, therapeutic success is mainly limited by the high degree of genetic and phenotypic heterogeneity, the blood brain barrier (BBB), as well as increased drug resistance. Temozolomide (TMZ), a monofunctional alkylating agent, is the first line chemotherapeutic drug for GBM treatment. Yet, the therapeutic efficacy of TMZ suffers from its inability to cross the BBB and very short half-life (~2 h), which requires high doses of this drug for a proper therapeutic effect. Encapsulation in a (nano)carrier is a promising strategy to effectively improve the therapeutic effect of TMZ against GBM. Although research on liposomes as carriers for therapeutic agents is still at an early stage, their integration in GBM treatment has a great potential to advance understanding and treating this disease. In this review, we provide a critical discussion on the preparation methods and physico-chemical properties of liposomes, with a particular emphasis on TMZ-liposomal formulations targeting GBM developed within the last decade. Furthermore, an overview on liposome-based formulations applied to translational oncology and clinical trials formulations in GBM treatment is provided. We emphasize that despite many years of intense research, more careful investigations are still needed to solve the main issues related to the manufacture of reproducible liposomal TMZ formulations for guaranteed translation to the market.

show abstract

Section: Targeting Liposomesmentioning

confidence: 99%

Section: Thin-film Hydration (Thf)mentioning

confidence: 99%

Section: Physico-chemical Propertiesmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Liposomal-Based Formulations: A Path from Basic Research to Temozolomide Delivery Inside Glioblastoma Tissue

et al. 2022

View full text Add to dashboard Cite

show abstract

“…For example, in a study conducted by Zhang et al, glucose-functionalized liposomes (gLTP) that co-load TMZ and pro-apoptotic peptide (PAP) can cross the BBB through the glucose-GLUT1 pathway to deliver these drugs to the tumor site. PAP affects the mitochondria reducing ATP generation, while enhancing the sensitivity of GBM cells to TMZ [226]. In the same way, Papachristdoulou et al delivered, via liposomes, O6-(4-bromothenyl) guanine derivates (O6BTG) targeting MGMT to enhance TMZ efficacy in vitro [227].…”

mentioning

confidence: 99%

Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment

et al. 2022

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is a grade IV glioma considered the most fatal cancer of the central nervous system (CNS), with less than a 5% survival rate after five years. The tumor heterogeneity, the high infiltrative behavior of its cells, and the blood–brain barrier (BBB) that limits the access of therapeutic drugs to the brain are the main reasons hampering the current standard treatment efficiency. Following the tumor resection, the infiltrative remaining GBM cells, which are resistant to chemotherapy and radiotherapy, can further invade the surrounding brain parenchyma. Consequently, the development of new strategies to treat parenchyma-infiltrating GBM cells, such as vaccines, nanotherapies, and tumor cells traps including drug delivery systems, is required. For example, the chemoattractant CXCL12, by binding to its CXCR4 receptor, activates signaling pathways that play a critical role in tumor progression and invasion, making it an interesting therapeutic target to properly control the direction of GBM cell migration for treatment proposes. Moreover, the interstitial fluid flow (IFF) is also implicated in increasing the GBM cell migration through the activation of the CXCL12-CXCR4 signaling pathway. However, due to its complex and variable nature, the influence of the IFF on the efficiency of drug delivery systems is not well understood yet. Therefore, this review discusses novel drug delivery strategies to overcome the GBM treatment limitations, focusing on chemokines such as CXCL12 as an innovative approach to reverse the migration of infiltrated GBM. Furthermore, recent developments regarding in vitro 3D culture systems aiming to mimic the dynamic peritumoral environment for the optimization of new drug delivery technologies are highlighted.

show abstract

Saponin‐Encapsulated Microbubbles Protect Dopaminergic Neurons from MPTP‐Induced Oxidative Stress Injury

Zhang

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

Parkinson's disease (PD) is starting at younger ages. In order to reduce the risk of PD in young people, Rb3 is selected as an active ingredient and assembled into Rb3 nanoparticles (Rb3NPs)encapsulated microbubbles (MBs), shorted for Rb3NPs@MBs. This study uses focused ultrasound‐mediated Rb3NPs@MBs to cross the blood–brain barrier and reach the brain lesions to be intervened in in order to explore the prevention of 1‐methyl‐4‐phenyl‐4‐piperidinpropionate ester (MPTP)‐induced PD by Rb3NPs@MBs and its related mechanisms. In the present study, Rb3NPs@MBs prevent MPTP‐induced tyrosine hydroxylase (TH)‐positive cell decreases, decrease TH expression, increase Park2 expression, and decrease expression of α‐synaptonucleoprotein in the pars compactus nigra (SNc). It is found, in vitro study, that Rb3NPs treatment significantly reverses MPTP‐induced apoptosis and death of PC12/SY5Y cells, which is commonly used mouse/ human neural cell lines. It is also found that Rb3NPs@MBs can prevent the production of reactive oxygen species (ROS) in SNc. Finally, it is found that DJ‐1 expression decreases after Rb3NPs@MBs are introduced. Results suggest that the neuroprotective activity of Rb3NPs@MBs may be achieved by increasing the expression of DJ‐1 and decreasing the production of ROS. Taken together, these data reveal that Rb3NPs@MBs play an important role in preventing memory deficiency in PD.

show abstract

Blood–brain barrier penetrating liposomes with synergistic chemotherapy for glioblastoma treatment

Abstract: Glioblastoma multiforme (GBM) is an aggressive and malignant brain tumor with high mortality. Current treatment strategies are still unsatisfactory on this devastating disease. Here, we developed a glucose-functionalized liposome (gLTP)...

Cited by 25 publications

References 37 publications

Liposomal-Based Formulations: A Path from Basic Research to Temozolomide Delivery Inside Glioblastoma Tissue

Liposomal-Based Formulations: A Path from Basic Research to Temozolomide Delivery Inside Glioblastoma Tissue

Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment

Saponin‐Encapsulated Microbubbles Protect Dopaminergic Neurons from MPTP‐Induced Oxidative Stress Injury

Contact Info

Product

Resources

About